Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

ck is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.

During the first half of 2013 the Company will be having discussions with regulatory authorities regarding future clinical development plans for ibrutinib's use in patients with DLBCL. The Company expects to be able to provide further updates in the third quarter of 2013.

Conference Call and further Corporate UpdatesThe Company will hold a conference call today at 4:30 p.m. EST. To participate in the conference call, please dial 1-877-407-0778 for domestic callers and 1-201-689-8565 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at http://www.pharmacyclics.com.

Use of Non-GAAP Financial MeasuresThis press release contains non-GAAP financial measures, including operating expenses and other expenses adjusted to exclude certain non-cash expenses. These measures are not in accordance with, or an alternative to generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction w
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks can ... Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original Equipment ... increase healthcare worker safety and reduce financial costs. , CTI Electronics announces a ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)...  Today, Americord Registry, one of the fastest growing cord ... a partner at Kirkland & Ellis LLP, as the newest ... http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We are thrilled about ... Martin Smithmyer , CEO of Americord. "He brings a wealth ... assist Americord,s growth and vision." Andrew Horne ...
(Date:6/30/2015)... ... , ... The maximum number of shares proposed to be purchased in the ... unvested restricted stock). On June 29, 2015, the last trading day prior to the ... the OTCBB was $2.29 per share. , The tender offer will expire on July ...
Breaking Biology Technology:Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3Americord Registry Announces Andrew Horne as Advisory Board Member 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... All amounts are in U.S. dollars, QUEBEC ... AEZS; TSX: AEZ;), a global biopharmaceutical company focused ... completed the sale,of its Quebec City property for ... AEterna Zentaris also entered into a long-term lease ...
... 27 /Xinhua-PRNewswire-FirstCall/ -- China Clean,Energy Inc. (OTC ... a leading producer of environmentally-friendly specialty,chemical products ... Republic of,China, today announced that it continues ... its specialty chemical products and that it,continues ...
... New spray-on films developed by UC San Diego chemists ... quickly reveal trace amounts of nitrogen-based explosives. , Contaminated ... blue under ultraviolet light. One of the films can ... that could provide evidence to help solve a crime, ...
Cached Biology Technology:AEterna Zentaris Sells Quebec City Building for $7.1 million 2China Clean Energy Updates Business Outlook 2China Clean Energy Updates Business Outlook 3Glowing films developed by UC San Diego chemists reveal traces of explosives 2
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... chemicals may one day be synthesised using biotechnology, following ... provide soldier beetles with their potent predator defence system., ... published details of the gene identification breakthrough and potential ... ., "For the first time, our team has been ...
... A study conducted by scientists at the Royal Botanic Gardens, ... climate change alone could lead to the extinction of wild ... of this century. Wild Arabica is considered important ... considerable genetic diversity. The Arabicas grown in the world,s coffee ...
... causes lung-damaging inflammation in cystic fibrosis (CF), and that ... finding offers a potential new drug target for treating ... illness and death for people with CF. "Developing ... big step forward," says Dr. Stuart Turvey, who led ...
Cached Biology News:Gene find turns soldier beetle defence into biotech opportunity 2New study suggests that Arabica coffee could be extinct in the wild within 70 years 2New study suggests that Arabica coffee could be extinct in the wild within 70 years 3New study suggests that Arabica coffee could be extinct in the wild within 70 years 4New study suggests that Arabica coffee could be extinct in the wild within 70 years 5New drug target found for cystic fibrosis lung disease 2
... This antibody is specific for human cardiac troponin ... the Ca-binding signals responsible for contraction of cardiac ... troponin complex in human cells. It also cross-reacts ... Antigen: Highly purified human ...
... N-(2-Naphthoyl)-Val-phenylalaninal 2-Naphthoyl-VF-CHO White ... INERT GAS. A cell-permeable, reversible inhibitor of ... x-40 (ED 50 = 2.6 ... = 2.7 μM) in HEK293 cells ...
cystatin A (N-18)...
...
Biology Products: